Relevant disclosures attached

Pat Growth 25pctEbitda Margin ExpansionEmphasis Of MatterExceptional ItemRelated Party TransactionsResults View source PDF

FORTIS · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

+0.5%1-day move

₹961.90

prior close

₹969.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

+0.6+1.3+1.5+0.9+0.5+0.0-2.6-3.4-3.0-2.2+0.8-0.9-2.0—

Up moveDown movePending

AI summary

Fortis Healthcare's Board approved audited consolidated financial results for FY ended March 2026. Revenue from operations grew 17.3% to ₹91,278 lakhs from ₹77,828 lakhs in FY25. Net profit increased 31.5% to ₹10,642 lakhs from ₹8,094 lakhs. EBITDA rose 29% to ₹21,356 lakhs with margins expanding to 23.4% from 21.3%. EPS improved to ₹13.80 from ₹10.26. The Board recommended a final dividend of ₹1 per share (10% on ₹10 face value). Statutory auditors B S R & Co. LLP issued an unmodified opinion. The auditor's report includes an Emphasis of Matter on ongoing SFIO investigation regarding alleged improper transactions by erstwhile promoters (pre-2018) and a Supreme Court order directing forensic audit of RHT Health Trust transactions.

Likely market impact

Strong financial performance with 31.5% PAT growth and margin expansion is positive for shareholders. However, the ongoing regulatory investigations and related party transaction concerns noted in the Emphasis of Matter section create lingering governance risks that investors should monitor.